The Subject Expert Committee (SEC) is scheduled to meet on Wednesday to discuss Dr Reddy’s application seeking emergency use approval for the Sputnik V coronavirus vaccine.
Dr Reddy's has been working with the Russian Direct Investment Fund (RDIF) to hold small clinical trials of Sputnik V in India.
The vaccine has proved 91.6% effective against Covid-19, based on late-stage trials in Russia, results published in the Lancet medical journal showed .
More than a million people in Russia have received Sputnik V, which is marketed abroad by the RDIF and has been approved for emergency use in Algeria, Argentina, Bolivia, Mexico and Serbia.
RDIF expects India, the world's biggest vaccine maker, to produce about 300 million doses of Sputnik V this year. Hetero Biopharma is making more than 100 million doses.
Published 24 February 2021, 04:59 IST